Suzhou Ribo Life Science Co., Ltd.
蘇州瑞博生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

ON-MARKET SHARE REPURCHASE UNDER THE SHARE REPURCHASE MANDATE

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

Reference is made to the voluntary announcement (the "**Announcement**") of the Company dated June 8, 2026 in relation to, among other things, the intention of the board (the "**Board**") of directors (the "**Directors**") of the Company to repurchase H shares of the Company (the "**H Shares**") from time to time on the open market (the "**Share Repurchase**"), pursuant to the general mandate to repurchase H Shares (the "**Share Repurchase Mandate**") granted by the shareholders of the Company (the "**Shareholders**") at the annual general meeting of the Company held on June 5, 2026. Unless otherwise stated, capitalized terms used herein shall have the same meanings as defined in the Announcement.

The Board hereby announces that, pursuant to the Share Repurchase Mandate, the Company repurchased a total of 186,600 H Shares on the open market on July 13, 2026, for a total consideration of HK$9,301,200. All such repurchased H Shares are held as treasury shares.

The Board believes that the Share Repurchase in the present market conditions will demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to the Shareholders. The Share Repurchase was conducted under circumstances which the Board considers to be appropriate and in the interest of the Company and the Shareholders as a whole. The Company may further repurchase H Shares as and when appropriate in compliance with all applicable laws and regulations.

Shareholders and potential investors of the Company should note that the Share Repurchase is subject to market conditions and at the absolute discretion of the Board. There is no guarantee as to the timing, number or price of any Share Repurchase. Therefore, Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, July 13, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.